Mobile

A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003052-36

A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immunological memory following primary vaccination with either GSK Biologicals’ selected 3µg 18C-TT containing 11Pn-PD-DiT vaccine formulation or the 11Pn-PD vaccine or Prevenar™, through the administration of a single dose of unconjugated 23-valent pneumococcal polysaccharide vaccine (Pneumovax™). To assess the immune response of a booster dose of GSK Biologicals’ 10Pn-PD-DiT vaccine administered to children 12-23 months of age following primary vaccination with one of the 8 other GSK Biologicals’ 11Pn-PD-DiT vaccine formulations.

Critère d'inclusion

  • Booster vaccination against Streptococcus pneumoniae in healthy children having previously received vaccines as a primary 3-dose vaccination course in the study 11PN-PD-DIT-002

Liens